Digestive Diseases and Sciences

, Volume 57, Issue 3, pp 791–800 | Cite as

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience

  • Muslim Atiq
  • Manoop S. Bhutani
  • Mehmet Bektas
  • Jeffrey E. Lee
  • Yun Gong
  • Eric P. Tamm
  • Chintan P. Shah
  • William A. Ross
  • James Yao
  • Gottumukkala S. Raju
  • Xuemei Wang
  • Jeffrey H. LeeEmail author
Original Article



Pancreatic neuroendocrine tumors (PNET) are fairly uncommon. Recent data highlight the importance of EUS in diagnosis of PNET. With this background, we decided to review our experience from a tertiary cancer center with regard to the presentation and clinical features of PNET and the diagnostic utility of EUS-FNA in this scenario.


We identified patients who underwent EUS at our institution between January 1st 2001 and December 31st 2009 for a suspected PNET. Data on clinical features, cross-sectional imaging findings, EUS findings, and cytology results were collected.


A total of 81 patients were referred for EUS-FNA for a suspected PNET. Mean age was 58.1 years. There were 41 (50.6%) males. PNET was found incidentally in 38 (46.9%) patients. Computed tomography scanning identified a pancreatic mass in 72 out of 79 (91.1%) cases. Mean diameter of the largest lesion seen on EUS was 27.5 mm (range: 6.9–80 mm). The most common site (34; 42%) was the head of the pancreas. EUS-FNA correctly confirmed a PNET in 73 out of 81 cases with diagnostic accuracy of 90.1%. Seven (8.6%) out of 81 patients had functional lesions, including three gastrinomas and four insulinomas. Liver metastases were found in 31 out of 81 (38.3%) cases. Of the 31 patients with liver metastasis, the mean diameter of lesions on EUS was 33.9 mm compared with 23.5 mm in patients without liver metastasis (P = 0.005).


EUS-FNA is a reliable modality for further characterization of suspected lesions and for establishing a tissue diagnosis. The occurrence of complications of EUS-FNA in this setting is low. Non-functional PNET are more frequently encountered than functional PNET.


Pancreatic neuroendocrine tumors Endoscopic ultrasound Fine needle aspiration MEN-1 Insulinomas 


  1. 1.
    O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34:324–332.PubMedCrossRefGoogle Scholar
  2. 2.
    Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011;36:35–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594–618.PubMedCrossRefGoogle Scholar
  4. 4.
    Gullo L, Migliori M, Falconi M, et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435–2439.PubMedCrossRefGoogle Scholar
  5. 5.
    Davies K, Conlon KC. Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep. 2009;11:119–127.PubMedCrossRefGoogle Scholar
  6. 6.
    Gumbs AA, Moore PS, Falconi M, et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol. 2002;81:45–53 (discussion 54).PubMedCrossRefGoogle Scholar
  7. 7.
    Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics. 2010;30:1445–1464.PubMedCrossRefGoogle Scholar
  8. 8.
    Frankel WL. Update on pancreatic endocrine tumors. Arch Pathol Lab Med. 2006;130:963–966.PubMedGoogle Scholar
  9. 9.
    Ardengh JC, de Paulo GA, Ferrari AP. EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. Gastrointest Endosc. 2004;60:378–384.PubMedCrossRefGoogle Scholar
  10. 10.
    Jani N, Khalid A, Kaushik N, et al. EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc. 2008;67:44–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Figueiredo FA, Giovannini M, Monges G, et al. Pancreatic endocrine tumors: a large single-center experience. Pancreas. 2009;38:936–940.PubMedCrossRefGoogle Scholar
  12. 12.
    Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73:691–696.PubMedCrossRefGoogle Scholar
  13. 13.
    Gibril F, Doppman JL, Jensen RT. Recent advances in the treatment of metastatic pancreatic endocrine tumors. Semin Gastrointest Dis. 1995;6:114–121.PubMedGoogle Scholar
  14. 14.
    Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21:43–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling. AJR Am J Roentgenol. 1984;143:585–589.PubMedGoogle Scholar
  16. 16.
    Rappeport ED, Hansen CP, Kjaer A, Knigge U. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol. 2006;47:248–256.PubMedCrossRefGoogle Scholar
  17. 17.
    Ueno N, Tomiyama T, Tano S, et al. Utility of endoscopic ultrasonography with color Doppler function for the diagnosis of islet cell tumor. Am J Gastroenterol. 1996;91:772–776.PubMedGoogle Scholar
  18. 18.
    Gines A, Vazquez-Sequeiros E, Soria MT, et al. Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc. 2002;56:291–296.PubMedCrossRefGoogle Scholar
  19. 19.
    Martin RC, Kooby DA, Weber SM, et al. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011;15:175–183.PubMedCrossRefGoogle Scholar
  20. 20.
    Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71:951–959.PubMedCrossRefGoogle Scholar
  21. 21.
    Figueiredo FA, Giovannini M, Monges G, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70:907–914.PubMedCrossRefGoogle Scholar
  22. 22.
    Akatsu T, Aiura K, Shimazu M, et al. Endoscopic ultrasonography of nonfunctioning pancreatic islet cell tumors with histologic correlation. Hepatogastroenterology. 2004;51:1590–1594.PubMedGoogle Scholar
  23. 23.
    Duerr EM, Mizukami Y, Ng A, et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008;15:243–256.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakayama Y, Wada R, Yajima N, et al. Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas. 2010;39:1147–1154.PubMedCrossRefGoogle Scholar
  25. 25.
    O’Toole D, Couvelard A, Rebours V, et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:847–856.PubMedCrossRefGoogle Scholar
  26. 26.
    Kongkam P, Al-Haddad M, Attasaranya S, et al. EUS and clinical characteristics of cystic pancreatic neuroendocrine tumors. Endoscopy. 2008;40:602–605.PubMedCrossRefGoogle Scholar
  27. 27.
    Ahrendt SA, Komorowski RA, Demeure MJ, et al. Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg. 2002;6:66–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Goh BK, Ooi LL, Tan YM, et al. Clinico-pathological features of cystic pancreatic endocrine neoplasms and a comparison with their solid counterparts. Eur J Surg Oncol. 2006;32:553–556.PubMedCrossRefGoogle Scholar
  29. 29.
    Hernandez LV, Mishra G, Forsmark C, et al. Role of endoscopic ultrasound (EUS) and EUS-guided fine needle aspiration in the diagnosis and treatment of cystic lesions of the pancreas. Pancreas. 2002;25:222–228.PubMedCrossRefGoogle Scholar
  30. 30.
    Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271–2277.PubMedCrossRefGoogle Scholar
  31. 31.
    Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721–1726.PubMedCrossRefGoogle Scholar
  32. 32.
    Palazzo L, Roseau G, Salmeron M. Endoscopic ultrasonography in the preoperative localization of pancreatic endocrine tumors. Endoscopy. 1992;24:350–353.PubMedCrossRefGoogle Scholar
  33. 33.
    De Angelis C, Carucci P, Repici A, et al. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound. 1999;10:139–150.PubMedCrossRefGoogle Scholar
  34. 34.
    Gouya H, Vignaux O, Augui J, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987–992.PubMedGoogle Scholar
  35. 35.
    Alsohaibani F, Bigam D, Kneteman N, et al. The impact of preoperative endoscopic ultrasound on the surgical management of pancreatic neuroendocrine tumours. Can J Gastroenterol. 2008;22:817–820.PubMedGoogle Scholar
  36. 36.
    Bansal R, Tierney W, Carpenter S, et al. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 1999;49:19–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Muslim Atiq
    • 1
  • Manoop S. Bhutani
    • 1
  • Mehmet Bektas
    • 1
  • Jeffrey E. Lee
    • 2
  • Yun Gong
    • 3
  • Eric P. Tamm
    • 4
  • Chintan P. Shah
    • 1
  • William A. Ross
    • 1
  • James Yao
    • 5
  • Gottumukkala S. Raju
    • 1
  • Xuemei Wang
    • 6
  • Jeffrey H. Lee
    • 1
    Email author
  1. 1.Department of GastroenterologyMD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical OncologyMD Anderson Cancer CenterHoustonUSA
  3. 3.Department of PathologyMD Anderson Cancer CenterHoustonUSA
  4. 4.Department of RadiologyMD Anderson Cancer CenterHoustonUSA
  5. 5.Department of Medical OncologyMD Anderson Cancer CenterHoustonUSA
  6. 6.Department of BiostatisticsMD Anderson Cancer CenterHoustonUSA

Personalised recommendations